&#xa0;
[normal]Written evidence submitted by [bold]the BioIndustry Association[bold] (BIA) (RaD0011)[bold]&#xa0;[bold]About [bold]the BIA[bold]Established in 1989, the BIA exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterpri
[normal]ses trade. The BIA represents innovative healthcare-focused bioscience companies, including over ninety per cent of biotech medicines currently in clinical development in the UK. BIA members are at the forefront of innovative scientific developments target
[normal]ing areas of unmet medical need and this innovation will lead to 
[normal]better outcomes for patients,
[normal] the development of the knowledge economy, and economic growth. 
[normal]&#xa0;[bold]Summary[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]The Biomedical Catalyst[bold] 
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal] 
[normal] 
[normal]&#xa0;
[normal]&#xa0;[bold]&#xa0;[bold]Crowdfunding[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]The UK public markets[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]August 2013
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]              
[normal]